References
- V. Kumar and K. Roy, Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases, SAR QSAR Environ. Res. 31 (2020), pp. 511–526. doi:https://doi.org/10.1080/1062936X.2020.1776388.
- V. Mody, J. Ho, S. Wills, A. Mawri, L. Lawson, M.C.C.J.C. Ebert, G.M. Fortin, S. Rayalam, and S. Taval, Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents, Commun. Biol. 4 (2021), pp. 1–10. doi:https://doi.org/10.1038/s42003-020-01577-x.
- N. Adhikari, S. Banerjee, S.K. Baidya, B. Ghosh, and T. Jha, Ligand-based quantitative structural assessments of SARS-CoV-2 3CLpro inhibitors: An analysis in light of structure-based multi-molecular modeling evidences, J. Mol. Struct. 1251 (2022), pp. 132041. doi:https://doi.org/10.1016/j.molstruc.2021.132041.
- P. De, S. Bhayye, V. Kumar, and K. Roy, In silico modeling for quick prediction of inhibitory activity against 3CLpro enzyme in SARS CoV diseases, J. Biomol. Struct. Dyn. 17 (2020), pp. 1–27.
- P.S. Saxena, K. Singh, P. Jangir, M.N. Tripathi, V. Singh, U. Yadav, and A. Srivastava, Perspectives for potential therapies for SARS-CoV-2: Review of the present literature, Ijqspr 6 (2021), pp. 1–24.
- P.K. Ojha, S. Kar, J.G. Krishna, K. Roy, and J. Leszczynski, Therapeutics for COVID-19: From computation to practices—where we are, where we are heading to, Mol. Divers. 25 (2020), pp. 1–35.
- P.M. Khan, V. Kumar, and K. Roy, In silico modeling of small molecule carboxamides as inhibitors of SARS-CoV 3CL protease: An approach towards combating COVID-19, Comb. Chem. High T. Scr. 24 (2021), pp. 1281–1299.
- O.O. Elekofehinti, O. Iwaloye, O.R. Molehin, and C.D. Famusiwa, Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation, Silico Pharmacol. 1 (2021), pp. 1–9.
- M.E. Zaki, S.A. Al-Hussain, V.H. Masand, S. Akasapu, S.O. Bajaj, N.N. El-Sayed, A. Ghosh, and I. Lewaa, Identification of Anti-SARS-CoV-2 compounds from food using qsar-based virtual screening, molecular docking, and molecular dynamics simulation analysis, Pharmaceuticals 4 (2021), pp. 357. doi:https://doi.org/10.3390/ph14040357.
- A.S. de Souzade Souza, R.F. de Souza, and C.R. Guzzo, Quantitative structure-activity relationships, molecular docking and molecular dynamics simulations reveal drug repurposing candidates as potent SARS-CoV-2 main protease inhibitors, J. Biomol. Struct. Dyn. 24 (2021), pp. 1–8. doi:https://doi.org/10.1080/07391102.2021.1958700.
- D. Luo, J.B. Tong, X. Zhang, X.C. Xiao, and S. Bian, Computational strategies towards developing novel SARS-CoV-2 Mpro inhibitors against COVID-19, J. Mol. Struct. 12 (2022), pp. 131378. doi:https://doi.org/10.1016/j.molstruc.2021.131378.
- J. Qiao, Y.-S. Li, R. Zeng, F.-L. Liu, R.-H. Luo, C. Huang, Y.-F. Wang, J. Zhang, B. Quan, C. Shen, and X. Mao, SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model, Science 371 (2021), pp. 1374–1378. doi:https://doi.org/10.1126/science.abf1611.
- C.H. Zhang, K.A. Spasov, R.A. Reilly, K. Hollander, E.A. Stone, J.A. Ippolito, M.E. Liosi, M.G. Deshmukh, J. Tirado-Rives, S. Zhang, and Z. Liang, Optimization of triarylpyridinone inhibitors of the main protease of SARS-CoV-2 to low-nanomolar antiviral potency, ACS Med. Chem. Lett. 12 (2021), pp. 1325–1332. doi:https://doi.org/10.1021/acsmedchemlett.1c00326.
- M. Kuzikov, E. Costanzi, J. Reinshagen, F. Esposito, L. Vangeel, M. Wolf, B. Ellinger, C. Claussen, G. Geisslinger, A. Corona, and D. Iaconis, Identification of inhibitors of SARS-CoV-2 3CL-pro enzymatic activity using a small molecule in vitro repurposing screen, ACS Pharmacol. Trans. Sci. 4 (2021), pp. 1096–1110.
- C.H. Zhang, E.A. Stone, M. Deshmukh, J.A. Ippolito, M.M. Ghahremanpour, J. Tirado-Rives, K.A. Spasov, S. Zhang, Y. Takeo, S.N. Kudalkar, and Z. Liang, Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations, ACS Cent. Sci. 7 (2021), pp. 467–475. doi:https://doi.org/10.1021/acscentsci.1c00039.
- B. Bai, A. Belovodskiy, M. Hena, A.S. Kandadai, M.A. Joyce, H.A. Saffran, J.A. Shields, M.B. Khan, E. Arutyunova, J. Lu, and S.K. Bajwa, Peptidomimetic α-acyloxymethylketone warheads with six-membered lactam P1 glutamine mimic: SARS-CoV-2 3CL protease inhibition, coronavirus antiviral activity, and in vitro biological stability, J. Med. Chem. 65 (2021), pp. 2905–2925.
- S.H. Han, C.M. Goins, T. Arya, W.J. Shin, J. Maw, A. Hooper, D.P. Sonawane, M.R. Porter, B.E. Bannister, R.D. Crouch, and A.A. Lindsey, Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease (SARS-CoV-2 3CLpro), J. Med. Chem. 65 (2021), pp. 2880–2904.
- C.S. Dampalla, Y. Kim, N. Bickmeier, A.D. Rathnayake, H.N. Guyen, J. Zheng, M.M. Kashipathy, M.A. Baird, K.P. Battaile, S. Lovell, and S. Perlman, Structure-guided design of conformationally constrained cyclohexane inhibitors of severe acute respiratory syndrome coronavirus-2 3CL protease, J. Med. Chem. 64 (2021), pp. 10047–10058. doi:https://doi.org/10.1021/acs.jmedchem.1c00319.
- M. Kuzikov, E. Costanzi, J. Reinshagen, F. Esposito, L. Vangeel, M. Wolf, B. Ellinger, C. Claussen, G. Geisslinger, A. Corona, and D. Iaconis, Identification of inhibitors of SARS-CoV-2 3CL-pro enzymatic activity using a small molecule in vitro repurposing screen, ACS Pharmacol. Transl. Sci. 4 (2021), pp. 1096–1110. doi:https://doi.org/10.1021/acsptsci.0c00216.
- W. Zhu, M. Xu, C.Z. Chen, H. Guo, M. Shen, X. Hu, P. Shinn, C. Klumpp-Thomas, S.G. Michael, and W. Zheng, Identification of SARS-CoV-2 3CL protease inhibitors by a quantitative high-throughput screening, ACS Pharmacol. Trans. Sci. 3 (2020), pp. 1008–1016. doi:https://doi.org/10.1021/acsptsci.0c00108.
- V. Kumar, P.K. Ojha, A. Saha, and K. Roy, Exploring 2D-QSAR for prediction of beta-secretase 1 (BACE1) inhibitory activity against Alzheimer’s disease, SAR QSAR Environ. Res. 31 (2020), pp. 87–133. doi:https://doi.org/10.1080/1062936X.2019.1695226.
- Alvascience, alvaDesc (software for molecular descriptors calculation) version 2.0.6, 2021, https://www.alvascience.com (accessed November 02, 2021).
- I.N. Minitab, MINITAB statistical software, Minitab Release 13 (2000). Available at http://www.minitab.com/en-us/products/minitab/ (accessed November 02, 2021).
- A. Tropsha, Best practices for QSAR model development, validation, and exploitation, Molec. Inf. 29 (2010), pp. 476–488. doi:https://doi.org/10.1002/minf.201000061.
- SIMCA | Umetrics. Available at: https://umetrics.com/products/simca (accessed December 10, 2021).
- V. Kumar, P. De, P.K. Ojha, A. Saha, and K. Roy, A multi-layered variable selection strategy for QSAR modeling of butyrylcholinesterase inhibitors, Curr. Top. Med. Chem. 20 (2020), pp. 1601–1627. doi:https://doi.org/10.2174/1568026620666200616142753.
- Discovery studio predictive science application | dassault systèmes BIOVIA. https://www.3dsbiovia.com/products/collaborative-science/biovia-discovery-studio/ (accessed November 10, 2021).
- R.B. Aher and K. Roy, QSAR and pharmacophore modeling of diverse aminothiazoles and aminopyridines for antimalarial potency against multidrug-resistant Plasmodium falciparum, Med. Chem. Res. 23 (2014), pp. 4238–4249. doi:https://doi.org/10.1007/s00044-014-0997-x.
- A.T. Ton, F. Gentile, M. Hsing, F. Ban, and A. Cherkasov, Rapid identification of potential inhibitors of SARS‐CoV‐2 main protease by deep docking of 1.3 billion compounds, Mol. Inform. 39 (2020), pp. 2000028. doi:https://doi.org/10.1002/minf.202000028.
- E. De Clercq and G. Li, Approved antiviral drugs over the past 50 years, I 29 (2016), pp. 695–747.
- Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Y. Zhao, B. Zhang, X. Li, L. Zhang, C. Peng, and Y. Duan, Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors, Nature 582 (2020), pp. 289–293. doi:https://doi.org/10.1038/s41586-020-2223-y.
- D.E. Pires, T.L. Blundell, and D.B. Ascher, pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures, J. Med. Chem. 58 (2015), pp. 4066–4072. doi:https://doi.org/10.1021/acs.jmedchem.5b00104.
- P. Banerjee, A.O. Eckert, A.K. Schrey, and R. Preer, ProTox-II: A webserver for the prediction of toxicity of chemicals, Nucleic Acids Res. 46 (2018), pp. W257–263. doi:https://doi.org/10.1093/nar/gky318.
- M.J. Abraham, T. Murtola, R. Schulz, S. Páll, J.C. Smith, B. Hess, and E. Lindahl, GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers, SoftwareX1 (2015), pp. 19–25.
- J. Huang, S. Rauscher, G. Nawrocki, T. Ran, M. Feig, B.L. De Groot, H. Grubmüller, and A.D. MacKerell, CHARMM36m: An improved force field for folded and intrinsically disordered proteins, Nat. Meth. 14 (2017), pp. 71–73. doi:https://doi.org/10.1038/nmeth.4067.
- V. Zoete, M.A. Cuendet, A. Grosdidier, and O. Michielin, SwissParam: A fast force field generation tool for small organic molecules, J. Comput. Chem. 32 (2011), pp. 2359–2368. doi:https://doi.org/10.1002/jcc.21816.
- W.L. Jorgensen, J. Chandrasekhar, J.D. Madura, R.W. Impey, and M.L. Klein, Comparison of simple potential functions for simulating liquid water, J. Chem. Phys. 79 (1983), pp. 926–935. doi:https://doi.org/10.1063/1.445869.
- B. Hess, H. Bekker, H.J. Berendsen, and J.G. Fraaije, LINCS: A linear constraint solver for molecular simulations, J. Comput. Chem. 18 (1997), pp. 1463–1472. doi:https://doi.org/10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H.
- C. Chen, Y. Huang, X. Ji, and Y. Xiao, Efficiently finding the minimum free energy path from steepest descent path, J. Chem. Phys. 138 (2013), pp. 164122. doi:https://doi.org/10.1063/1.4799236.
- A.M. Herrera-Rodríguez, V. Miletić, C. Aponte-Santamaría, and F. Gräter, Molecular dynamics simulations of molecules in uniform flow, Biophys. J. 116 (2019), pp. 1579–1585. doi:https://doi.org/10.1016/j.bpj.2018.12.025.
- S. Chatterjee, A. Maity, S. Chowdhury, M.A. Islam, R.K. Muttinini, and D. Sen, In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme, J. Biomol. Struct. Dyn. 30 (2020), pp. 1–4.
- M.S. Valdés-Tresanco, M.E. Valdés-Tresanco, P.A. Valiente, and E. Moreno, gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS, J. Chem. Theory Comput. 17 (2021), pp. 6281–6291. doi:https://doi.org/10.1021/acs.jctc.1c00645.
- E.B. de Melo, J.P. Martins, T.C. Jorge, M.C. Friozi, and M.M. Ferreira, Multivariate QSAR study on the antimutagenic activity of flavonoids against 3-NFA on Salmonella typhimurium TA98, Eur. J. Med. Chem. 45 (2010), pp. 4562–4569. doi:https://doi.org/10.1016/j.ejmech.2010.07.017.
- I. Moriguchi, S. Hirono, Q. Liu, I. Nakagome, and Y. Matsushita, Simple method of calculating octanol/water partition coefficient, Chem. Pharm. Bull. 40 (1992), pp. , 127–130. doi:https://doi.org/10.1248/cpb.40.127.
- I. Moriguchi, S. Hirono, I. Nakagome, and H. Hirano, Comparison of reliability of log P values for drugs calculated by several methods, Chem. Pharm. Bull. 42 (1994), pp. 976–978. doi:https://doi.org/10.1248/cpb.42.976.
- R. Aalizadeh, C. Peter, and N.S. Thomaidis, Prediction of acute toxicity of emerging contaminants on the water flea Daphnia magna by ant colony optimization–support vector machine QSTR models, Environ. Sci. Proc. Imp.19 (2017), pp. 438–448.